BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Astellas commits up to $124M to license Universal cell therapy tech
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Astellas commits up to $124M to license Universal cell therapy tech
Oct. 23, 2017
By
Michael Fitzhugh
No Comments
Astellas Pharma Inc.’s U.S.-based regenerative medicine center has agreed to pay Seattle-based Universal Cells Inc. up to $124 million for global rights to use its Universal Donor Cell technology in a new cell therapy for an undisclosed indication.
BioWorld